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Background: Genetic factors plays an important role in early failure of total hip arthroplasty (THA) etiology and
MMP-1 gene polymorphism rs5854 may be involved. The present study was conducted to reveal the possible
association between MMP-1 rs5854 C/T polymorphism and the risk of early failure of THA (aseptic loosening).
Methods: The rs5854 single nucleotide polymorphism (SNP) in MMP-1 gene was genotyped in 63 subjects who
were diagnosed as aseptic loosening after total hip arthroplasty within 10 years and in 81 age and gender
matched controls.
Results: The genotype frequencies of the MMP-1 rs5854 C/T polymorphism were 57.1% (CC), 28.6% (CT), and 14.3%
(TT) in patients with failure of THA, and 79.0% (CC), 17.3% (CT), and 3.7% (TT) in the controls (P = 0.0099). Rs5854
polymorphism was found to be significantly associated with increased risk of aseptic loosening.
Conclusion: The results showed the rs5854 SNP was associated with increased risk of the early aseptic loosening
susceptibility.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_177
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Total hip arthroplasty (THA) has become the gold stand-
ard treatment for patients with end stage arthritis [1].
Multiple studies have demonstrated that THA improved
the physical function and quality of life significantly [2-4].
Indications for THA have increased in the last decades,
along with the number of procedures performed annually.
Almost 1 million of THA was implanted worldwide annu-
ally, with a predicting increase of 174% to nearly 600,000
THA procedures annually by 2030 in the United States
[5-7]. However, indispensable proportion of patients after
THA still face the complications that may lead to the pre-
mature prosthesis failure and revision surgery, with a sig-
nificant impact on quality of life [5]. While sepsis, fracture,
and dislocation are relatively rare, aseptic loosening that* Correspondence: hjz3734@vip.sina.com
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unless otherwise stated.arising from aseptic inflammatory reactions to the pros-
thetic implants accounts for 75.7% of all THA revisions
[8-10]. The implanted prosthesis stimulates mesenchymal
cells to inflammatory response and osteoclast accumula-
tion, leading eventually to excessive resorption, bone loss,
and periprosthetic osteolysis [11,12].
The loosening of prosthetic implants can be attributed
to biological, physical and biophysical factors, however, the
precise aetiology remains unclear. At present, it is thought
that the individual difference of susceptibility to aseptic
loosening results from a combination of environmental
and genetic factors. Environmental factors include type of
prosthesis, implant design, material, surgical technique,
fixation method, and postoperative rehabilitation proced-
ure have been widely studied [13,14], but more and more
attention is paid to the genetic factors like single nucleo-
tide polymorphisms (SNPs). SNPs are genetic variations
that are considered biologically normal and can be found
in at least 1% of the population, which may contribute. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conditions [15,16]. Various gene SNPs of GNAS1, TNF-
238, TNF-a, IL6-174, MMP1, MMP2, and et al. were re-
ported to be associated with increased prosthetic loosening.
Matrix metalloproteases (MMPs), which are secreted by
inflammatory cells in response to stimuli from lipopoly-
saccharides and cytokines [17], are the biggest class of en-
zymes responsible for metabolism of the extracellular
matrix(ECM) [18]. MMP-1 performs an important func-
tion in collagen degradation including collagen types I, II,
and IX, which are the most abundant protein components
of the ECM [18-21]. Previous researches have demon-
strated that proteases were present in the peri-implant
fluid and might perform a pathological role in peri-
implant bone loss [21]. Interstitial collagenase follows the
osteoblasts at the start of the bone reabsorption, thus gen-
erating collagen fragments and activating the osteoclasts
[22]. MMP-1 is usually expressed at low levels but it is in-
duced by phorbol esters, growth factors, and inflammatory
cytokines [23]. Previous studies have demonstrated the
polymorphism in the promoter of the MMP-1 gene was
associated with early implant failure of THA [24]. Simi-
larly, the C allele and C/C genotype of the MMP-1 SNP
rs5854 was found highly associated with aseptic failure
[25]. However, further research is needed to replicate pre-
vious findings. This study aims to determine whether the
MMP-1 SNP rs5854 was associated with failure of THA
(aseptic loosening) in Chinese Han Populations.
Method
This study was approved by the ethics committee of the
Xiangya Hospital, and informed consent was obtained
from all the patients and control participants.
Study population
The present study enrolled 63 patients who were diag-
nosed as aseptic loosening of prosthetic hip joints at the
Department of Orthopaedics of Xiangya Hospital, China.
Strict inclusion and exclusion criteria was used for all
these patients. Entry criteria for this study including clin-
ical, radiological, laboratory, and intrasurgical diagnosis of
aseptic loosening within the first 10 years after total hip
arthroplasties. The diagnostic criteria for aseptic loosening
of the prosthesis was listed as the following: 1. Hip pain
when walking or moving the joint. 2. Migration of pros-
thetic components or bone radiolucency around the pros-
thesis of more than 2 mm. 3. Inflammatory tests within
normal patterns — erythrocyte sedimentation rate, poly-
merase chain reaction (PCR), and leukogram. Patients
were excluded if they had any deep infection or the suspi-
cion of implant infection, traumatic loosening, inflamma-
tory diseases, or immunosuppress ant agents after THA in
their history. The control group consists of 81 age- and
gender- matched patients who had undergone THA thathad been proved to be therapeutically successful over
long-term follow-up (at least 10 years). All subjects in-
cluded in this study were Chinese Han Population.
Genotyping
DNA samples were obtained from all the participants
from peripheral blood with the Chelex-100 method [26].
The MMP-1 SNP rs5854 was then genotyped using Taq-
man assay (Applied Biosystems 7500, ABI, Foster City,
CA) and dual-labeled probes in real-time PCR. The
primers and probes were designed and synthesized by
Sigma (Sigma-Proligo, The Woodlands, TX). Genotyping
was performed by independent laboratory personnel who
was blinded to the study, and three authors independently
reviewed the genotyping results, data entry, and statistical
analyses. In addition, we randomly selected 5% samples of
case and control subjects for reproducibility tests at least
twice in different days and yielded a 100% concordant.
Statistical analysis
The Statistical Package for Social Sciences software (SPSS,
Inc., Chicago, IL, USA), version 16.0 for Windows. The
demographic and clinical data were presented as Mean ±
SD and compared between groups by the Student’s t‑tests
and Chi‑square test. The genotype and allelic frequencies
were evaluated by Hardy‑Weinberg equilibrium and com-
pared by the Chi‑square test. The association between the
MMP-1 rs5854 polymorphism and failure of THA was
assessed under the following genetic models, which were
treated as a dichotomous variable: (i) T-allele versus C-
allele for allele level comparison; (ii) CT +TT versus CC
for a dominant model of the T allele; (iii) TT versus CT +
CC for a recessive model of the T-allele; and (iv) TT versus
CC for the extreme genotype. Multivariate logistic regres-
sion was used to estimate odds ratios (ORs) and 95% con-
fidence intervals (CI) after adjustment for age and gender.




Demographic data of the population studied and the
number of individuals in each group were shown in
Table 1. There were no significant differences between
groups in terms of age, gender, and BMI. There were 17
patients with a early aseptic loosening of the total hip
prosthesis during the first five years after surgery. And
the remaining 46 patients developed aseptic failure dur-
ing five to ten years after surgery.
Association of MMP-1 rs5854 polymorphism with
susceptibility to failure of THA
As expected, the distribution of the genotype of MMP-1
SNP rs5854 conformed to the Hardy–Weinberg equilibrium








Female/Male 28/35 33/48 n.s
Age (years, Female/Male) 70.8±9.7/71.6±9.0 72.0±6.3/72.6±7.1 n.s




0-5 17 / /
5-10 46 / /
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the genotyped and allele distributions of the SNP rs5854
for the cases and controls. The genotype frequencies of
the MMP-1 rs5854 C/T polymorphism were 57.1% (CC),
28.6% (CT) and 14.3% (TT) in failure of THA patients,
and 79.0% (CC), 17.3% (CT) and 3.7% (TT) in controls
(P = 0.0099). Multivariate logistic regression was used to
estimate odds ratios (ORs) and 95% confidence intervals
(CI) after adjustment for age and gender. For allele level
comparison, the MMP-1 SNP rs5854 T allele was associ-
ated with an increased risk of aseptic loosening in terms
of the frequency of allele comparison (T vs. C:OR = 2.72;
95% CI =2.06 – 3.48, P <0.0001). For a dominant model of
the T allele, the CT + TT genotypes were associated with
the risk for aseptic loosening (CT + TT vs. CC, OR = 2.67,
95% CI = 1.25 - 5.76, P = 0.0028). For a recessive model of
the T allele, the TT homozygote genotype was associated
with susceptibility to aseptic loosening (TT vs. CT + CC.
OR= 4.17, 95% CI =1.22 - 17.2, P = 0.0186). For the ex-
treme genotype, the TT genotypes were associated with
the risk for aseptic loosening (TT vs. CC, OR = 5.13, 95%
CI = 1.33 to 19.8 P = 0.0113).
Additionally, the association analysis was also per-
formed in regarding with the period before aseptic loos-
ening happens. Significant association was found in
terms of the comparison of the frequency of allele and
comparison with a dominant model. However, no signifi-
cant association were found with the dominant model
and for the extreme genotype comparison Table 3.Table 2 The genotype and allele distributions of the MMP-1 S
Group Allele (%)
CC CT TT CT + TT
Control 64 14 3 17
Case 36 18 9 27
ORa (95% CI) / / 5.13 (1.33 to 19.8) 2.67 (1.25 to 5.76)
Pa / / 0.0113 0.0028
aORs and 95% CIs were estimated using multiple logistic regression analyses and adDiscussion
The present study was conducted to reveal the possible
association between MMP-1 rs5854 C/T polymorphism
and the risk of early failure of THA (aseptic loosening).
The results showed the rs5854 SNP was associated with
increased risk of the aseptic loosening susceptibility.
Although total hip prosthetic implants improve quality
of life significantly for most patients, they are not built to
last forever. Importantly, aseptic loosening due to the peri-
prosthetic osteolysis is known to be the main complication
of early failure after THA. Aseptic loosening has been
considered to introduced by biological, microbiological,
and biomechanical factors. However, the mechanisms and
causes of early failure of THA results from aseptic loosen-
ing continue to be a matter of study. Nowadays, the ab-
normal immunological responses were considered as the
core of the pathologies.
Abnormal immunological response that participated in
destroy of the peri-implant tissues involves almost all
immunological cells like macrophages, endothelial cells,
fibroblasts, osteoclasts, and osteoblasts [27,28]. When
activated, these cells may synthesize various cytokines
and lipid mediators that involve inflammatory and asep-
tic periprosthetic osteolysis processes [13,29,30]. Though
the inflammatory cytokines trigger a chronic inflamma-
tory status, it may also determine soft tissue and sup-
porting bone damage if untreated [8,9].
MMPs is one of the cytokines and lipid mediators that
increase the destruction of the peri-implant proteolytic tis-
sue [31-33]. The effect of MMPs may be produced by the
direct degradation of the extracellular organic matrix of
bone. The expression of MMP-13 was found in macro-
phages, endothelial cells, and fibroblasts of the synovial-
like membrane around the implant [34]. Local mRNA
expression profile also demonstrated that MMP-1, −9, −10,
−12 and −13 were strongly elevated in aseptic loosening
compared to the controls; MMP-2, −7, −8, −11, −14, −15,
−16, −17 and −19 were moderately expressed, whereas
MMP-3 expression was lower and MMP-20 very low [35].
Furthermore, collagen degradation in periprosthetic tissue
correlated significantly with the number of local MMP-1,
MMP-13 and cathepsin K-positive cells [36].
Individual susceptibility to aseptic loosening after THA is
partly determined by patient-related factors, namely, theNP rs5854 for the cases and controls
CT + CC TT C T H-WE
78 3 87.7 12.3 n.s
54 9 71.4 28.6 /
/ 4.17 (1.22 to 17.2) / 2.72 (2.06 to 3.48) /
/ 0.0186 / < 0.0001 /
justed for age, gender and BMI.




CC CT TT CT + TT CT + CC TT C T
0-5 5 8 4 12 13 4 52.9 47.1
5-10 31 10 5 15 41 5 78.3 21.7
ORa (95% CI) / / 0.23 (0.12 to 1.16) 0.15 (0.08 to 0.43) / 0.37 (0.09 to 1.47) / 0.28 (0.10 to 0.40)
Pa / / 0.0750 0.0025 / 0.1762 / < 0.0001
aORs and 95% CIs were estimated using multiple logistic regression analyses and adjusted for age, gender and BMI.
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ences may be contributed to the polymorphisms of various
genes encoding cytokines involved in the development of
aseptic loosening [24,37,38]. Polymorphism of the genes
that express MMPs is associated with development of ovar-
ian cancer, endometrial carcinoma, changes in tooth
mineralization, premature rupture of the fetal membrane
and severe periodontiti [19,20,39,40]. Recently, Malik and
co-workers reported the association of a MMP-1 SNP
rs5854 and the occurrence of increased aseptic loosening
susceptibility [25]. Similarly, this study demonstrated posi-
tive association between MMP-1 SNP rs5854 and aseptic
loosening susceptibility, moreover, it seemed also to be as-
sociated with earlier occurrence of aseptic loosening.
The MMP-1 SNP rs5854 exists within a promoter re-
gion of the gene and thus have a direct effect on the
amount and function of gene expression [41]. However,
the exact mechanisms and effects of SNP rs5854 on
MMP gene regulation are still not fully delineated. Pro-
teolysis of extracellular matrix components can affect
cell–cell communication and cell apoptosis. Degradation
products of collagen and matrix components are chemo-
tactic for monocytes, which may lead to the aggravation
of inflammatory reaction in the periprosthetic tissues.
The present study demonstrated MMP-1 rs5854 C/T
polymorphism was associated with increased risk of early
failure of THA (aseptic loosening). It may be help in un-
derstanding the pathologies of aseptic loosening. More-
over, the evaluation of MMP-1 rs5854 SNP may be help in
the diagnosis and prevention of aseptic loosening. How-
ever, there is some limitation in the present study. The
most important is the relatively small sample size. The
subgroup analysis according to the period before aseptic
loosening happens did not show significant association,
which may be result from the relative small sample size in
the groups. Additionally, a single center case– control
study is not sufficient to fully interpret the relationship be-
tween MMP-1 polymorphisms and susceptibility to asep-
tic loosening. Further prospective study with multiple
population and larger sample size is needed.
Conclusion
The present study was conducted to reveal the possible
association between MMP-1 rs5854 C/T polymorphismand the risk of early failure of THA (aseptic loosening).
The results showed the rs5854 SNP was associated with
increased risk of the early aseptic loosening susceptibility.
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